Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques

Vaccine

Volumn 29, Issue 5, 2011, Pages 931-940

  Carroll, Timothy D ^a,b   Matzinger, Shannon R ^a,b   Barro, Mario ^f   Fritts, Linda ^a,b   McChesney, Michael B ^b,d   Miller, Christopher J ^a,b,c   Johnston, Robert E ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Global Vaccines Inc   (United States)

Author keywords

Animal model; Antibody and cellular immunity; Influenza vaccine; Viral adjuvants

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; REPLICON; RHESUS MONKEY; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-2; MACACA MULATTA; MALE; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PRIMATE DISEASES; TRACHEA; VACCINES, INACTIVATED;

EID: 78751580569     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.024     Document Type: Article

References (49)

1. Thompson J.M., Whitmore A.C., Konopka J.L., Collier M.L., Richmond E.M., Davis N.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 2006, 103(March (10)):3722-3727.
2. Thompson J.M., Whitmore A.C., Staats H.F., Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 2008, 26(September (39)):4998-5003.
3. Thompson J.M., Nicholson M.G., Whitmore A.C., Zamora M., West A., Iwasaki A., et al. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol 2008, 181(July (1)):574-585.
4. Wright P.F., Neumann G., Kawaoka Y. Orthomyxoviruses. Fields Virology 2007, 1691-1740. Wolters Kluwer/Lippincott Williams & Wilkins. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
5. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(November (22)):2295-2301.
6. Palache A.M., Beyer W.E., Osterhaus A.D. Influenza vaccine dosages. Vaccine 2008, 26(May (19)):2305-2306.
7. Kemble G., Greenberg H. Novel generations of influenza vaccines. Vaccine 2003, 21(May (16)):1789-1795.
8. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22(August (23-24)):3136-3143.
9. Hayashi M., Satou E., Ueki R., Yano M., Miyano-Kurosaki N., Fujii M., et al. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator. Biochem Biophys Res Commun 2005, 329(April (1)):230-236.
10. Lay M., Callejo B., Chang S., Hong D.K., Lewis D.B., Carroll T.D., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone((R))) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, (May).
11. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19(March (17-19)):2673-2680.
12. Rimmelzwaan G.F., Claas E.C., van Amerongen G., de Jong J.C., Osterhaus A.D. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999, 17(March (11-12)):1355-1358.
13. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(December (2)):389-401.
14. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000, 74(January (2)):914-922.
15. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007, 25(November (48)):8180-8189.
16. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28(December (2)):484-493.
17. Hartley C.A., Reading P.C., Ward A.C., Anders E.M. Changes in the hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence for mice. Arch Virol 1997, 142(1):75-88.
18. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G.P., Kobasa D., et al. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009, 83(April (8)):3843-3851.
19. Maines T.R., Jayaraman A., Belser J.A., Wadford D.A., Pappas C., Zeng H., et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009, 325(July (5939)):484-487.
20. Svitek N., Rudd P.A., Obojes K., Pillet S., von Messling V. Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction. Virology 2008, 376(June (1)):53-59.
21. Lowen A.C., Mubareka S., Steel J., Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 2007, 3(October (10)):1470-1476.
22. Carroll T.D., Matzinger S.R., Genesca M., Fritts L., Colon R., McChesney M.B., et al. Interferon-induced expression of MxA in the respiratory tract of rhesus macaques is suppressed by influenza virus replication. J Immunol 2008, 180(February (4)):2385-2395.
23. Rimmelzwaan G.F., Baars M., van Beek R., van Amerongen G., Lovgren-Bengtsson K., Claas E.C., et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 1997, 78(April (Pt 4)):757-765.
24. Rimmelzwaan G.F., Kuiken T., van Amerongen G., Bestebroer T.M., Fouchier R.A., Osterhaus A.D. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001, 75(July (14)):6687-6691.
25. Kobasa D., Jones S.M., Shinya K., Kash J.C., Copps J., Ebihara H., et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445(January (7125)):319-323.
26. LoBue A.D., Thompson J.M., Lindesmith L., Johnston R.E., Baric R.S. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 2009, 83(April (7)):3212-3227.
27. Reed L.J., Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938, 27(3):493-497.
28. Spackman E., Senne D.A., Myers T.J., Bulaga L.L., Garber L.P., Perdue M.L., et al. Development of a real-time reverse transcriptase PCR Assay for Type A Influenza Virus and the Avian H5 and H7 hemagglutinin subtypes. Journal of Clinical Microbiology 2002, 40(September (9)):3256-3260.
29. Lifson J.D., Rossio J.L., Piatak M., Parks T., Li L., Kiser R., et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001, 75(November (21)):10187-10199.
30. Miller C.J., McChesney M.B., Lu X., Dailey P.J., Chutkowski C., Lu D., et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 1997, 71(March (3)):1911-1921.
31. Webster RG, Cox N, Stöhr K. WHO Manual on Animal Influenza Diagnosis and Surveillance, 1st ed. In: Response CDSa, editor. World Health Organization, 2002: 28-36.
32. Genesca M., Rourke T., Li J., Bost K., Chohan B., McChesney M.B., et al. Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239. J Immunol 2007, 179(October (7)):4732-4740.
33. Genesca M., Skinner P.J., Bost K.M., Lu D., Wang Y., Rourke T.L., et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol 2008, 1(May (3)):219-228.
34. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 2003, 115:63-73.
35. Clements M.L., Snyder M.H., Buckler-White A.J., Tierney E.L., London W.T., Murphy B.R. Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. J Clin Microbiol 1986, 24(July (1)):47-51.
36. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(February (2)):148-158.
37. Brandtzaeg P., Kiyono H., Pabst R., Russell M.W. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008, 1(January (1)):31-37.
38. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl.)):S45-53.
39. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004, 113(April (7)):998-1007.
40. Egan M.A., Chong S.Y., Hagen M., Megati S., Schadeck E.B., Piacente P., et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004, 22(September (27-28)):3774-3788.
41. Enioutina E.Y., Visic D., McGee Z.A., Daynes R.A. The induction of systemic and mucosal immune responses following the subcutaneous immunization of mature adult mice: characterization of the antibodies in mucosal secretions of animals immunized with antigen formulations containing a vitamin D3 adjuvant. Vaccine 1999, 17(August (23-24)):3050-3064.
42. Gockel C.M., Bao S., Beagley K.W. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol 2000, 37(June (9)):537-544.
43. McCluskie M.J., Weeratna R.D., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002, 32(February (3)):179-185.
44. Moran T.P., Burgents J.E., Long B., Ferrer I., Jaffee E.M., Tisch R.M., et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007, 25(September (36)):6604-6612.
45. Leitner W.W., Hwang L.N., deVeer M.J., Zhou A., Silverman R.H., Williams B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003, 9(January (1)):33-39.
46. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14(April (4)):461-470.
47. Tovey M.G., Lallemand C., Meritet J.F., Maury C. Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine 2006, 24(April (Suppl. 2)). S2-46-7.
48. Crotty S., Johnston R.J., Schoenberger S.P. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010, 11(February (2)):114-120.
49. King C., Tangye S.G., Mackay C.R. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008, 26:741-766.